Cerevel Therapeutics Holdings shares are trading lower after Mizuho maintained a Neutral rating on the stock and lowered its price target from $29 to $25.
Portfolio Pulse from Benzinga Newsdesk
Cerevel Therapeutics Holdings' stock is trading lower after Mizuho maintained a Neutral rating on the stock and lowered its price target from $29 to $25.
August 07, 2023 | 2:55 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Cerevel Therapeutics' stock price is likely to be negatively impacted in the short term due to Mizuho's lowered price target.
Mizuho, a reputable financial institution, has maintained a Neutral rating on Cerevel Therapeutics but lowered its price target from $29 to $25. This suggests that Mizuho sees less upside potential in the stock, which could lead to selling pressure and a decrease in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100